3963 MAPLE AVENUE, DALLAS, TX
2026 Annual Meeting Results - Stockholders Elect Class II Directors
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
RSM US LLP Appointed As Independent Auditor; Deloitte Dismissed
Financial Results, Press Release
Termination of License Agreement with ImmuneOnco - Axion Bio, Inc.
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Definitive Revised Proxy Statement
Correspondence
Submission Upload